





PHARMACEUTICAL 2022

CytomX Therapeutics Inc.
Rank 304 of 475



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 96% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -197%, being 79% points above the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 310,301 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 949 |
| Liabilities, Current | 106,316 |
| Liabilities, Non-Current | 143,716 |
| Other Assets | 22,201 |
| Other Compr. Net Income | -195 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | -83,632 |
| Property and Equipment | 5,960 |
| Research and Development | 114,194 |
| Revenues | 69,573 |
| Selling, General and Administrative Expense | 39,160 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 339,411 |
| Liabilities | 250,032 |
| Expenses | 153,354 |
| Stockholders Equity | 89,379 |
| Net Income | -167,413 |
| Comprehensive Net Income | -167,510 |
| Economic Capital Ratio | -197% |

